Turkish Abstract Abstract Article PDF Similar Articles

¹İstanbul Retina Enstitüsü, İstanbul, Doç. Dr.
²İstanbul Retina Enstitüsü, İstanbul, Uz. Dr.
³İstanbul Retina Enstitüsü, İstanbul, Prof. Dr. Purpose: To evaluate the results of intravitreal bevacizumab (IVB) therapy in patients with subfoveal choroidal neovascularization (CNV) due to pathologic myopia.
Materials and Methods: Visual acuity testing, systemic ophthalmologic examination, color photographs, fluorescein angiography (FFA), and optical coherence tomography (OCT) were used to evaluate the results of IVB therapy. Follow-up examinations were scheduled at 6 weeks, and at 3 and 6 months. Indications for retreatment were active leaking CNV shown by FFA and the presence of subretinal fluid by OCT in combination visual disturbance.
Results: Eight eyes of 8 patients with subfoveal CNV due to pathologic myopia were examined. Follow up ranged from 6 to 22 months with a mean of 11±6 months. At the last follow up all patients showed no leakage from CNV. No deterioration in visual acuity was observed in any case during follow-up. At the last follow-up examination, 7 eyes (88%) had gained at least 1 line of vision, 4 eyes of which had gained at least 2 lines of vision. Retreatment was not required in any patient after the initial treatment (6 weeks apart 3 times 1.25 mg IVB injection). IVB therapy did not cause any systemic or ocular complications.
Conclusion: Treatment of CNV related to pathologic myopia with IVB therapy achieves cessation of fluorescein leakage from CNV and stabilizes or improves visual acuity. Keywords : pathologic myopia, subfoveal choroidal neovascularization, intravitreal bevacizumab therapy